Brainsway Ltd. reached a profitability inflection in fiscal 2025, posting net income of $7.6 million on revenue of $52.2 million, a 27 percent increase from the prior year and the second consecutive year of positive earnings after a decade of losses. The Jerusalem-based medical device company, which develops and commercializes Deep Transcranial Magnetic Stimulation systems for major depressive disorder, obsessive-compulsive disorder, and smoking addiction, has demonstrated consistent quarterly revenue acceleration through 2025 with Q4 reaching $14.5 million. Operating cash flow turned meaningfully positive at $17.5 million, and the company ended the year with $67.7 million in cash against an accumulated deficit of $90.8 million.
The investment thesis rests on three variables. The Deep TMS revenue trajectory and the indications expansion is the load-bearing revenue variable, with fiscal 2025 revenue of $52.2 million growing 27 percent year over year and quarterly run-rate exiting the year at $58 million annualized, and the strategic intent is to drive adoption across the three FDA-cleared indications while pursuing additional clearances, and the market will track quarterly revenue by indication, system placements, lease versus sale mix, and average selling price trends as real-time indicators. The operating leverage and the path to sustained profitability is the load-bearing margin variable, with gross margin stable at 75 percent, R&D at 18 percent of revenue, sales and marketing at 38 percent, and net income margin of 14 percent in 2025, and the strategic intent is to maintain gross margin while scaling the commercial infrastructure to absorb fixed costs, and the market will track quarterly operating expense ratios, R&D intensity, sales force productivity, and operating margin trajectory as real-time indicators. The cash runway and the capital structure sustainability is the load-bearing balance sheet variable, with $67.7 million cash, $17.5 million operating cash flow, no funded debt, and an accumulated deficit of $90.8 million that will take years to extinguish at current earnings rates, and the strategic intent is to fund operations organically while maintaining the Nasdaq listing and the Israeli Innovation Authority grant relationships, and the market will track quarterly cash position, operating cash flow conversion, grant income, and any equity raise activity as real-time indicators.